- Home
- GTBP vs SNGX Comparison
GTBP vs SNGX Comparison
Compare GTBP & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- SNGX
- Stock Information
- Founded
- GTBP 1965
- SNGX 1987
- Country
- GTBP United States
- SNGX United States
- Employees
- GTBP N/A
- SNGX N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- SNGX Health Care
- Exchange
- GTBP Nasdaq
- SNGX Nasdaq
- Market Cap
- GTBP 5.5M
- SNGX 6.5M
- IPO Year
- GTBP N/A
- SNGX 1987
- Fundamental
- Price
- GTBP $2.23
- SNGX $1.86
- Analyst Decision
- GTBP Strong Buy
- SNGX
- Analyst Count
- GTBP 1
- SNGX 0
- Target Price
- GTBP $11.00
- SNGX N/A
- AVG Volume (30 Days)
- GTBP 17.4K
- SNGX 26.0K
- Earning Date
- GTBP 05-15-2025
- SNGX 05-09-2025
- Dividend Yield
- GTBP N/A
- SNGX N/A
- EPS Growth
- GTBP N/A
- SNGX N/A
- EPS
- GTBP N/A
- SNGX N/A
- Revenue
- GTBP N/A
- SNGX $2,342.00
- Revenue This Year
- GTBP N/A
- SNGX N/A
- Revenue Next Year
- GTBP N/A
- SNGX N/A
- P/E Ratio
- GTBP N/A
- SNGX N/A
- Revenue Growth
- GTBP N/A
- SNGX N/A
- 52 Week Low
- GTBP $1.72
- SNGX $1.68
- 52 Week High
- GTBP $10.66
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- GTBP 46.01
- SNGX 38.46
- Support Level
- GTBP $2.30
- SNGX $1.83
- Resistance Level
- GTBP $2.37
- SNGX $2.00
- Average True Range (ATR)
- GTBP 0.15
- SNGX 0.10
- MACD
- GTBP -0.01
- SNGX -0.00
- Stochastic Oscillator
- GTBP 14.55
- SNGX 11.11
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).